VSCP exits Imedex

Vesey Street Capital Partners has sold Imedex to HMP. No financial terms were disclosed. Based in Alpharetta, Georgia, Imedex is a provider of accredited medical education for healthcare professionals.


NEW YORK, Sept. 5, 2017 /PRNewswire/ — Vesey Street Capital Partners, LLC (VSCP) announced today that it sold Imedex, LLC, an industry leader in the creation of independent, accredited medical education, to HMP, a leading healthcare education and events company. Terms of the agreement were not disclosed.

“Since our acquisition of Imedex in 2015, we and our Board worked hard with the company to develop and execute a strategy, to enhance focus, and to better leverage already existing assets. Now, following the significant progress we’ve made, we believe Imedex being part of the HMP family will position both companies well for many years to come,” said Adam Feinstein, Managing Partner of VSCP.

“Imedex’s unwavering commitment to improving patient care through its educational programming has made working with the company a gratifying experience. The company has a bright future ahead as it teams with HMP – an organization that understands this important mission,” added Steve Geringer, Chairman of Imedex under VSCP’s ownership.

“I’m grateful to the VSCP team for its guidance, hands-on approach, and deep healthcare industry experience which has contributed to Imedex’s success. I’m confident that the future is bright and very much look forward to the next chapter in partnership with HMP,” said Dan Lowrie, CEO of Imedex.

With the transaction complete, Imedex is now a fully owned subsidiary of HMP. Leadership includes Dan Lowrie, who assumed the title of president of Imedex, and Chris Bolwell, who assumed the title of executive vice president. The Imedex headquarters will remain in Alpharetta, GA.

Vesey Street Capital Partners is a dedicated Healthcare Services private equity firm that seeks to invests in middle market businesses that service Hospitals / Outpatient Facilities, Physicians and Payors. Specifically, we specialize in middle market buyouts and growth equity investments, with a focus on businesses with strong cash flow characteristics that create value for hospitals and physicians by enhancing efficiency, improving quality, reducing costs and expanding revenues. Since inception, the firm has deployed nearly $400 million in capital, primarily as a control investor.

Imedex® is an industry leader in the creation of independent, accredited medical education for healthcare professionals that improves patient care around the world. With an emphasis in oncology, hematology, and gastroenterology, the company develops high-quality scientific programming that translates the latest research into clinically relevant information. Imedex provides more than 50,000 e-learning experiences annually and since 2001, its live conferences have welcomed more than 100,000 attendees. The company operates in the United States, Europe, and Asia. For more information, visit imedex.com.